Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo

BMB Reports

Volumn 47, Issue 7, 2014, Pages 376-381

  Ku, Sae Kwang ^a   Bae, Jong Sup ^b  

^a Daegu Haany University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Coagulation cascade; Endothelium; Fibrinolysis; Purpurogallin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; FUSED ALICYCLIC AROMATIC COMPOUND; PLASMINOGEN ACTIVATOR INHIBITOR 1; PURPUROGALLIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOUSE; PARTIAL THROMBOPLASTIN TIME; THROMBOCYTE; TRANSPORT AT THE CELLULAR LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTICOAGULANTS; BENZOCYCLOHEPTENES; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; CELL SURVIVAL; CELLS, CULTURED; FACTOR XA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905915273     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.7.195     Document Type: Article

References (29)

1. Hoffman, M. M. and Monroe, D. M. (2005) Rethinking the coagulation cascade. Curr. Hematol. Rep. 4, 391-396.
2. Davie, E. W., Fujikawa, K. and Kisiel, W. (1991) The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 30, 10363-10370.
3. Davie, E. W. (1995) Biochemical and molecular aspects of the coagulation cascade. Thromb. Haemost. 74, 1-6.
4. Esmon, C. T. (2001) Role of coagulation inhibitors in inflammation. Thromb. Haemost. 86, 51-56.
5. Quinn, C., Hill, J. and Hassouna, H. (2000) A guide for diagnosis of patients with arterial and venous thrombosis. Clin. Lab. Sci. 13, 229-238.
6. Levi, M., Schultz, M. and van der Poll, T. (2011) Coagulation biomarkers in critically ill patients. Crit. Care Clin. 27, 281-297.
7. Abou-Karam, M. and Shier, W. T. (1999) Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall. Phytother. Res. 13, 337-340.
8. Das, M., Bickers, D. R. and Mukhtar, H. (1984) Plant phenols as in vitro inhibitors of glutathione S-transferase(s). Biochem. Biophys. Res. Commun. 120, 427-433.
9. Zeng, L. H. and Wu, T. W. (1992) Purpurogallin is a more powerful protector of kidney cells than Trolox and allopurinol. Biochem. Cell Biol. 70, 684-690.
10. Veser, J. (1987) Kinetics and inhibition studies of catechol O-methyltransferase from the yeast Candida tropicalis. J. Bacteriol. 169, 3696-3700.
11. Wu, T. W., Zeng, L. H., Wu, J. and Carey, D. (1991) Purpurogallin--a natural and effective hepatoprotector in vitro and in vivo. Biochem. Cell Biol. 69, 747-750.
12. Wu, T. W., Zeng, L. H., Wu, J., Fung, K. P., Weisel, R. D., Hempel, A. and Camerman, N. (1996) Molecular structure and antioxidant specificity of purpurogallin in three types of human cardiovascular cells. Biochem. Pharmacol. 52, 1073-1080.
13. Inamori, Y., Muro, C., Sajima, E., Katagiri, M., Okamoto, Y., Tanaka, H., Sakagami, Y. and Tsujibo, H. (1997) Biological activity of purpurogallin. Biosci. Biotechnol. Biochem. 61, 890-892.
14. Kim, T. H., Ku, S. K., Lee, I. C. and Bae, J. S. (2012) Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Rep. 45, 200-205.
15. Esmon, C. T. (2005) The interactions between inflammation and coagulation. Br. J. Haematol. 131, 417-430.
16. Sugo, T., Nakamikawa, C., Tanabe, S. and Matsuda, M. (1995) Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. J. Biochem. 117, 244-250.
17. Rao, L. V., Rapaport, S. I. and Lorenzi, M. (1988) Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71, 791-796.
18. Ghosh, S., Ezban, M., Persson, E., Pendurthi, U., Hedner, U. and Rao, L. V. (2007) Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J. Thromb. Haemost. 5, 336-346.
19. Philip-Joet, F., Alessi, M. C., Philip-Joet, C., Aillaud, M., Barriere, J. R., Arnaud, A. and Juhan-Vague, I. (1995) Fibrinolytic and inflammatory processes in pleural effusions. Eur. Respir. J. 8, 1352-1356.
20. Schleef, R. R., Bevilacqua, M. P., Sawdey, M., Gimbrone, M. A., Jr. and Loskutoff, D. J. (1988) Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 263, 5797-5803.
21. Hamaguchi, E., Takamura, T., Shimizu, A. and Nagai, Y. (2003) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 307, 987-994.
22. Lopez, S., Peiretti, F., Bonardo, B., Juhan-Vague, I. and Nalbone, G. (2000) Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152, 359-366.
23. Schouten, M., Wiersinga, W. J., Levi, M. and van der Poll, T. (2008) Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536-545.
24. Kim, T. H., Ku, S. K. and Bae, J. S. (2012) Antithrombotic and profibrinolytic activities of eckol and dieckol. J. Cell Biochem. 113, 2877-2883.
25. Kim, S. Y., Kim, S., Kim, J. M., Jho, E. H., Park, S., Oh, D. and Yun-Choi, H. S. (2011) PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Rep. 44, 140-145.
26. Nowak, P., Zbikowska, H. M., Ponczek, M., Kolodziejczyk, J. and Wachowicz, B. (2007) Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thromb. Res. 121, 163-174.
27. Bae, J. S. and Rezaie, A. R. (2008) Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100, 101-109.
28. Bae, J. S. (2011) Antithrombotic and profibrinolytic activities of phloroglucinol. Food Chem. Toxicol. 49, 1572-1577.
29. Dejana, E., Callioni, A., Quintana, A. and de Gaetano, G. (1979) Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb. Res. 15, 191-197.